Article

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

2021-03-06

Abstract excerpt

Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 70813047-753e-5059-ba3d-d7843e766b9a
DOI: 10.1101/2021.03.06.434193

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesDOI 10.1101/2021.03.06.434193Read

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variantSemantic proximity Read

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.Semantic proximity Read

Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variantsSemantic proximity Read

Reduced neutralization of B.1.351 variant SARS-CoV-2 by convalescent sera of COVID-19 patientsSemantic proximity Read

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodiesSemantic proximity Read

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variantSemantic proximity Read

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.Semantic proximity Read

Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited seraSemantic proximity Read

Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2Semantic proximity Read

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesSemantic proximity Read